After the publication of the revised edition, therapeutic drugs described in “Future Treatment”
were approved and important evidence for pharmacologic therapy and nonpharmacologic …

Cellular senescence within the cardiovascular system has, until recently, been understudied
and unappreciated as a factor in the development of age‐related cardiovascular diseases …

Purpose To perform a systematic umbrella review with meta-analysis to evaluate the
certainty of evidence on mortality risk associated with digoxin use in patients with atrial …

In this review, we evaluated the literature on the benefits and deleterious effects of digoxin in
heart failure (HF) with reduced ejection fraction (EF). Although digoxin was considered an …

Background: Whether digoxin is associated with increased mortality in atrial fibrillation (AF)
remains controversial. We aimed to assess the risk of mortality and clinical effects of digoxin …

Background Atrial fibrillation (AF) and heart failure with reduced ejection fraction (HFrEF) are
common cardiovascular conditions linked to significant health burdens. This review aims to …

The effect of digoxin and beta-blockers on cardiovascular outcomes and mortality remains
unclear. The study aimed to determine differences in cardiovascular (CV) outcomes and …

心房颤动(简称房颤) 是危害我国中老年人群健康的重要疾病, 与脑卒中, 死亡风险有关.
目前房颤的发生和发展可通过心房结构重构, 电重构, 炎症, 自主神经系统障碍, 非编码RNA …

Background: Heart failure (HF) is associated with frequent hospitalization and worse
prognosis. Prognosis factors and survival in very long-term follow-up have not been reported …

Heart failure (HF) represents a significant public health challenge worldwide, affecting
millions of individuals and imposing a substantial burden on health care systems. Despite …